Abstract
Background: Effective Medical Science Liaison (MSL) performance measurement requires a comprehensive framework that captures the multidimensional nature of MSL contributions to pharmaceutical organizations and healthcare systems.
Objective: To establish a three-pillar framework for MSL performance measurement encompassing value creation indicators, patient outcome linkage, and return on investment consciousness.
Methods: This conceptual framework was developed through analysis of current MSL performance measurement practices, integration of established business performance measurement principles, and consideration of pharmaceutical industry-specific requirements.
Results: The three-pillar framework provides a balanced approach to MSL performance measurement, addressing both strategic and operational requirements while maintaining focus on ultimate patient benefit. Each pillar contributes essential perspectives on MSL effectiveness and organizational value creation.
Conclusions: Implementation of the three-pillar framework enables more comprehensive and strategically aligned MSL performance measurement, supporting improved decision-making regarding MSL activities and resource allocation.
Keywords: MSL Performance, Value Creation, Patient Outcomes, Return on Investment, Performance Framework
Introduction
The complexity of Medical Science Liaison (MSL) roles demands equally sophisticated performance measurement approaches that capture multiple dimensions of value creation. Traditional single-metric approaches fail to reflect the multifaceted contributions MSLs make to pharmaceutical organizations, healthcare providers, and ultimately, patients (Dyer et al., 2025). A comprehensive framework must balance immediate operational requirements with long-term strategic value creation.
The proposed three-pillar framework addresses this complexity by establishing distinct but interconnected measurement domains: value creation indicators, patient outcome linkage, and return on investment consciousness. This framework ensures that MSL performance measurement captures both the immediate organizational benefits and the ultimate patient-centered outcomes that justify MSL activities.
Pillar 1: Value Creation Indicators
Value creation indicators focus on measuring how MSL activities generate tangible benefits for healthcare stakeholders. Unlike traditional activity metrics, value creation indicators assess the quality and impact of MSL contributions rather than their quantity. These indicators recognize that MSL success should be measured by the value delivered, not the effort expended.
Key value creation indicators include clinical evidence utilization rates, treatment optimization contributions, diagnostic accuracy improvements, and adverse event management enhancements. These metrics directly connect MSL activities to healthcare improvements, providing clear evidence of professional impact beyond simple interaction counting.
The Japan Pharmaceutical Manufacturers Association (2019) emphasizes that MSL activities should contribute to improving medical care quality and maximizing patient benefits. Value creation indicators operationalize this principle by measuring how effectively MSLs achieve these objectives through their scientific exchanges and collaborative activities.
Implementation of value creation indicators requires establishing baseline measurements of healthcare provider knowledge and clinical decision-making patterns, then tracking improvements attributable to MSL interactions. This approach transforms performance measurement from passive documentation to active value assessment.
Pillar 2: Patient Outcome Linkage
Patient outcome linkage establishes direct connections between MSL activities and improvements in patient health outcomes. This pillar acknowledges that the ultimate justification for MSL activities lies in their contribution to better patient care and improved health outcomes.
Patient outcome linkage operates through a causal chain: MSL activities → healthcare provider behavior change → improved clinical decision-making → enhanced patient outcomes. Each link in this chain must be measurable and attributable to MSL contributions. This requires sophisticated measurement approaches that can track outcomes across extended timeframes and multiple healthcare interactions.
Specific patient outcome indicators include quality of life improvements, treatment adherence rates, clinical effectiveness measures, and healthcare utilization optimization. These indicators require collaboration with healthcare providers and access to patient outcome data, making them more complex to implement but ultimately more meaningful than traditional metrics.
The temporal dimension of patient outcome linkage presents unique challenges, as MSL activities may not manifest in measurable patient improvements for weeks or months. Performance measurement systems must accommodate these delays while maintaining clear attribution links between MSL activities and patient outcomes.
Pillar 3: Return on Investment Consciousness
Return on investment (ROI) consciousness ensures that MSL performance measurement considers the economic efficiency of value creation activities. This pillar recognizes that pharmaceutical organizations operate under resource constraints and must optimize their investment in MSL activities for maximum patient and organizational benefit.
ROI consciousness in MSL performance measurement differs fundamentally from traditional sales ROI calculations. Instead of measuring revenue generation, MSL ROI focuses on the relationship between investment in MSL activities and the creation of patient and healthcare system value. This includes healthcare cost savings, productivity improvements, and patient satisfaction enhancements.
Specific ROI indicators include cost per patient outcome improvement, efficiency of clinical evidence dissemination, healthcare system cost savings attributable to MSL activities, and knowledge transfer effectiveness ratios. These indicators help organizations optimize their MSL investment strategies while maintaining focus on patient benefit.
ROI consciousness also encompasses opportunity cost considerations, ensuring that MSL activities represent the most effective use of organizational resources for achieving patient outcome objectives. This perspective supports strategic decision-making about MSL deployment and activity prioritization.
Integration Framework
The three pillars function most effectively when integrated into a coherent measurement system rather than implemented as independent metrics. Integration ensures that improvements in one pillar do not come at the expense of others and that overall MSL performance reflects balanced achievement across all three dimensions.
The integration framework employs a balanced scorecard approach, weighting each pillar according to organizational priorities and strategic objectives. This flexibility allows organizations to emphasize patient outcomes during product launch phases, focus on value creation during market development, or prioritize ROI during resource optimization periods.
Successful integration requires establishing clear relationships between the three pillars, recognizing that value creation and patient outcomes ultimately drive ROI, while ROI consciousness ensures sustainable and scalable value creation. This interdependence strengthens the overall measurement system by creating internal consistency checks and balances.
Conclusion
The three-pillar framework for MSL performance measurement provides a comprehensive approach to evaluating MSL effectiveness while maintaining focus on patient benefit and organizational value creation. By balancing value creation indicators, patient outcome linkage, and return on investment consciousness, organizations can develop more sophisticated and strategically aligned performance measurement systems.
Implementation of this framework requires organizational commitment to more complex but more meaningful performance measurement approaches. The investment in sophisticated measurement systems is justified by improved MSL effectiveness, better resource allocation decisions, and ultimately, enhanced patient outcomes.
Future development of this framework should focus on establishing standardized measurement methodologies for each pillar and developing industry benchmarks that enable comparative performance assessment across organizations and therapeutic areas.
References
Dyer, S., Hyder, C., & Kraemer, J. (2025). Challenges of key performance indicators and metrics for measuring medical science liaison performance: Insights from a global survey. Pharmacy, 13, 51. https://doi.org/10.3390/pharmacy13020051
Japan Pharmaceutical Manufacturers Association. (2019). Consensus statement on medical science liaison activities. JPMA.
Theron, P., Britland, M., Holder, D., Ikeda, Y., Rewers, R. F., & Tiku, A. (2021). Promoting best practices for medical science liaisons position statement from the APPA, IFAPP, MAPS and MSLS. Therapeutic Innovation & Regulatory Science, 55(6), 1139-1144.
About the author:
Yusuke Izumi, MBA
He is a results-driven Medical Operations and Excellence leader with nearly 20 years in pharma and biotech, spanning Senior MSL, MSL Lead, Field Medical Excellence, Medical Operations, and Medical Excellence & Medical Information leadership roles. He specializes in optimizing medical operations, orchestrating cross-functional delivery, and leading digital transformation to boost efficiency, compliance, and customer value, particularly in rare diseases. With deep expertise in medical information management, system implementation, and global–local regulatory alignment, he consistently designs cost-effective solutions that streamline processes and elevate stakeholder satisfaction.
A strategic, collaborative leader, he builds high-performing teams and embeds continuous improvement, standardization, and best practices across organizations. Known for reliability and pragmatism, he advances enterprise initiatives, strengthens field medical impact in rare disease portfolios, and delivers measurable outcomes aligned with organizational and customer objectives.
Have an opinion on this article? Send a message to the editor.